Prophylactic Erythropoietin for Neuroprotection in Very Preterm Infants: A Meta-Analysis Update

Department of Neonatology, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Frontiers in pediatrics. 2021;9:657228
Full text from:

Other resources

A meta-analysis update of randomized controlled trials investigating recombinant human erythropoietin suggests improved neurodevelopmental outcome in preterm infants. There was substantial heterogeneity, which could be ascribed to a single trial. Exclusion of this trial featuring a high risk of bias abolished heterogeneity and any effects of recombinant human erythropoietin treatment.
Study details
Study Design : Systematic Review
Language : eng
Credits : Bibliographic data from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine